How Many Tons of Medical Cannabis Poles Bought in 2023

In 2023, Poles showed that their interest in medical cannabis has significantly increased, reaching new records. Rafał Mundry, using data from the Ministry of Health, revealed that last year an impressive 4,658 kilograms of this pharmaceutical raw material was purchased in Poland. This is a number that not only attracts attention, but also makes us reflect on society’s changing attitude to medical cannabis.

Let’s analyze historical data to better understand this trend. Since 2019, we have observed a dynamic increase – from 33 kilograms in the first year, through 94 kilograms in 2020, to over 4,600 kilograms in 2023. The number of prescriptions filled also increased significantly, reaching almost 277,000 last year. This indicates growing confidence in the medical uses of cannabis and easier access to it for patients.

Read more about the imports of medical cannabis by Poles and find the most important cannabis news of the day with the Hemp.im mobile app.

How is such data collected?

Year of implementation Number of prescriptions filled Value Unit
2019 2,909 33,219 g
2020 7,137 94,038 g
2021 33,147 427 017 g
2022 108,847 1,167,752 g
2023 276 807 4,658,759 g

The Ministry of Health, together with the e-Health Center, has introduced a new analytical model that allows for more precise calculations. This is important because the quality and accuracy of data are crucial to understanding social trends and needs. However, it is worth remembering challenges such as differences in the quality of data provided by pharmacies, which may affect the overall interpretation of results.

Collecting medical cannabis data has its challenges, including differences in the quality of data provided by individual dispensaries. Not all information is verified by the National Health Fund, which may affect the overall analysis and interpretation of available data.

Conclusions and future prospects on the medical cannabis imports in Poland

The increased interest in medical cannabis in Poland in 2023 is not only a symptom of a change in social attitude, but also a signal for future research and market development. With the growing popularity of this raw material, it becomes important to conduct further research that may contribute to a better understanding of its properties and potential applications.

Record purchases of medical cannabis in Poland in 2023 are an important signal for patients, doctors and politicians. Market development and increased interest in pharmaceutical raw materials open up new therapeutic possibilities, while at the same time prompting reflection on the future of medicine and its directions of development. As society becomes more open to alternative forms of treatment, medical cannabis could play a key role in improving the quality of life for many patients.

__

(Featured image by Websi via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Fakty Konopne. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us